These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 34937518)

  • 1. All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies.
    Lodise TP; Bassetti M; Ferrer R; Naas T; Niki Y; Paterson DL; Zeitlinger M; Echols R
    Expert Rev Anti Infect Ther; 2022 May; 20(5):707-719. PubMed ID: 34937518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
    Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD
    Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence.
    Viale P; Sandrock CE; Ramirez P; Rossolini GM; Lodise TP
    Ann Intensive Care; 2023 Jun; 13(1):52. PubMed ID: 37322293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections.
    Syed YY
    Drugs; 2021 Sep; 81(13):1559-1571. PubMed ID: 34427896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cefiderocol: a first and novel class of siderophore cephalosporin for Carbapenem-resistant Gram-negative infection].
    Yamano Y; Morita I; Ariyasu M
    Nihon Yakurigaku Zasshi; 2024; 159(5):331-340. PubMed ID: 39218681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and
    Cruz-López F; Martínez-Meléndez A; Morfin-Otero R; Rodriguez-Noriega E; Maldonado-Garza HJ; Garza-González E
    Front Cell Infect Microbiol; 2022; 12():884365. PubMed ID: 35669117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections.
    Kanj SS; Bassetti M; Kiratisin P; Rodrigues C; Villegas MV; Yu Y; van Duin D
    Int J Antimicrob Agents; 2022 Sep; 60(3):106633. PubMed ID: 35787918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
    Portsmouth S; van Veenhuyzen D; Echols R; Machida M; Ferreira JCA; Ariyasu M; Tenke P; Nagata TD
    Lancet Infect Dis; 2018 Dec; 18(12):1319-1328. PubMed ID: 30509675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of combination therapy in the treatment of severe infections caused by carbapenem resistant gram-negatives: a systematic review of clinical studies.
    Savoldi A; Carrara E; Piddock LJV; Franceschi F; Ellis S; Chiamenti M; Bragantini D; Righi E; Tacconelli E
    BMC Infect Dis; 2021 Jun; 21(1):545. PubMed ID: 34107899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections.
    Doi Y
    Clin Infect Dis; 2019 Nov; 69(Suppl 7):S565-S575. PubMed ID: 31724043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence.
    Kollef M; Dupont H; Greenberg DE; Viale P; Echols R; Yamano Y; Nicolau DP
    Int J Antimicrob Agents; 2023 Aug; 62(2):106882. PubMed ID: 37301312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine).
    Paul M; Carrara E; Retamar P; Tängdén T; Bitterman R; Bonomo RA; de Waele J; Daikos GL; Akova M; Harbarth S; Pulcini C; Garnacho-Montero J; Seme K; Tumbarello M; Lindemann PC; Gandra S; Yu Y; Bassetti M; Mouton JW; Tacconelli E; Rodríguez-Baño J
    Clin Microbiol Infect; 2022 Apr; 28(4):521-547. PubMed ID: 34923128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Off-label use versus formal recommendations of conventional and novel antibiotics for the treatment of infections caused by multidrug-resistant bacteria.
    Jean SS; Liu IM; Hsieh PC; Kuo DH; Liu YL; Hsueh PR
    Int J Antimicrob Agents; 2023 May; 61(5):106763. PubMed ID: 36804370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) on the diagnosis and antimicrobial treatment of infections due to carbapenem-resistant Gram-negative bacteria.
    Pintado V; Ruiz-Garbajosa P; Aguilera-Alonso D; Baquero-Artigao F; Bou G; Cantón R; Grau S; Gutiérrez-Gutiérrez B; Larrosa N; Machuca I; Martínez Martínez L; Montero MM; Morte-Romea E; Oliver A; Paño-Pardo JR; Sorlí L
    Enferm Infecc Microbiol Clin (Engl Ed); 2023; 41(6):360-370. PubMed ID: 36522272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections.
    Eljaaly K; Alharbi A; Alshehri S; Ortwine JK; Pogue JM
    Drugs; 2019 Feb; 79(3):243-269. PubMed ID: 30723876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New antimicrobial treatment options for severe Gram-negative infections.
    Hetzler L; Kollef MH; Yuenger V; Micek ST; Betthauser KD
    Curr Opin Crit Care; 2022 Oct; 28(5):522-533. PubMed ID: 35942725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is it time to move away from polymyxins?: evidence and alternatives.
    Soman R; Bakthavatchalam YD; Nadarajan A; Dwarakanathan HT; Venkatasubramanian R; Veeraraghavan B
    Eur J Clin Microbiol Infect Dis; 2021 Mar; 40(3):461-475. PubMed ID: 33009595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of the newly approved antimicrobial agent Cefiderocol against Carbapenem resistant Gram negative clinical isolates.
    Khanchandani H; Chaudhury M; Rao MS; Ramakrishna N; Venkataramana B; Chaudhury A
    Indian J Med Microbiol; 2024; 48():100556. PubMed ID: 38447857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.